Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 14,952 Shares of Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Michele Farmer sold 14,952 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.63, for a total transaction of $24,371.76. Following the transaction, the insider owned 219,092 shares of the company’s stock, valued at approximately $357,119.96. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michele Farmer also recently made the following trade(s):

• On Tuesday, February 17th, Michele Farmer sold 35,215 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.58, for a total value of $55,639.70.

Pacific Biosciences of California Price Performance

Pacific Biosciences of California stock traded up $0.05 during midday trading on Thursday, reaching $1.68. The company’s stock had a trading volume of 4,308,048 shares, compared to its average volume of 7,583,859. The company has a current ratio of 6.24, a quick ratio of 5.40 and a debt-to-equity ratio of 17.88. The stock has a market cap of $507.21 million, a PE ratio of -0.91 and a beta of 2.27. Pacific Biosciences of California, Inc. has a 52 week low of $0.85 and a 52 week high of $2.73. The business has a 50-day moving average price of $2.02 and a 200-day moving average price of $1.77.

Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. The company had revenue of $44.65 million for the quarter, compared to the consensus estimate of $44.60 million. Pacific Biosciences of California had a negative net margin of 341.47% and a negative return on equity of 251.75%. On average, sell-side analysts predict that Pacific Biosciences of California, Inc. will post -0.72 EPS for the current year.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Management will participate in a TD Cowen health-care conference fireside chat on March 2, providing a near-term investor event where the company may update guidance, commercialization progress, or product cadence — a potential catalyst if management delivers constructive news. Read More.
• Neutral Sentiment: Despite the sales, insiders retain large holdings after the transactions (final reported post-sale holdings: Michele Farmer ~219k shares; Christian O. Henry ~2.67M shares; Oene Mark Van ~1.74M shares), which may signal liquidity-taking rather than full exits. (See SEC filings below for details.)
• Negative Sentiment: Heavy insider selling reported Feb. 17–18: combined sales by multiple executives totaled roughly 707,731 shares for about $1.13M. Notable filings: Christian O. Henry sold ~472,667 shares across two trades, Michele Farmer sold ~50,167 shares, and Oene Mark Van sold ~184,897 shares — each reducing their stakes by mid-single to low-double-digit percentages. Large, clustered insider sales can raise investor concern about near-term outlook or signal personal diversification, and may pressure sentiment until management commentary clarifies reasons. SEC filings: Christian O. Henry Read More.; Michele Farmer Read More.; Oene Mark Van Read More..

Analyst Ratings Changes

PACB has been the subject of several recent research reports. Piper Sandler upped their price target on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a research note on Thursday, January 22nd. Stephens boosted their target price on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the company an “overweight” rating in a report on Monday, November 10th. Finally, Barclays increased their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $2.20.

Institutional Investors Weigh In On Pacific Biosciences of California

Large investors have recently bought and sold shares of the stock. Amiral Gestion acquired a new stake in Pacific Biosciences of California in the second quarter valued at approximately $3,208,000. Geode Capital Management LLC raised its holdings in shares of Pacific Biosciences of California by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 6,718,879 shares of the biotechnology company’s stock worth $8,333,000 after acquiring an additional 401,637 shares during the last quarter. XTX Topco Ltd lifted its position in Pacific Biosciences of California by 95.5% in the 2nd quarter. XTX Topco Ltd now owns 954,596 shares of the biotechnology company’s stock valued at $1,184,000 after acquiring an additional 466,359 shares in the last quarter. Carret Asset Management LLC acquired a new position in Pacific Biosciences of California during the 2nd quarter valued at about $391,000. Finally, Financial Advocates Investment Management acquired a new position in Pacific Biosciences of California during the 2nd quarter valued at about $50,000.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.